001     274005
005     20250127091428.0
024 7 _ |a pmc:PMC11647431
|2 pmc
024 7 _ |a 10.1111/epi.18171
|2 doi
024 7 _ |a pmid:39470733
|2 pmid
024 7 _ |a 0013-9580
|2 ISSN
024 7 _ |a 1528-1167
|2 ISSN
024 7 _ |a altmetric:169884304
|2 altmetric
037 _ _ |a DZNE-2024-01433
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Bauer, Tobias
|0 P:(DE-2719)9002598
|b 0
|e First author
245 _ _ |a Proof of concept: Portable ultra-low-field magnetic resonance imaging for the diagnosis of epileptogenic brain pathologies.
260 _ _ |a Oxford [u.a.]
|c 2024
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1734528493_1124
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a High-field magnetic resonance imaging (MRI) is a standard in the diagnosis of epilepsy. However, high costs and technical barriers have limited adoption in low- and middle-income countries. Even in high-income nations, many individuals with epilepsy face delays in undergoing MRI. Recent advancements in ultra-low-field (ULF) MRI technology, particularly the development of portable scanners, offer a promising solution to the limited accessibility of MRI. In this study, we present and evaluate the imaging capability of ULF MRI in detecting structural abnormalities typically associated with epilepsy and compare it to high-field MRI at 3 T.Data collection was conducted within 3 consecutive weeks at the University Hospital Bonn. Inclusion criteria were a minimum age of 18 years, diagnosed epilepsy, and clinical high-field MRI with abnormalities. We used a .064 T Swoop portable MR Imaging System. Both high-field MRI and ULF MRI scans were evaluated independently by two experienced neuroradiologists as part of their clinical routine, comparing pathology detection and diagnosis completeness.Twenty-three individuals with epilepsy were recruited. One subject presented with a dual pathology. Across the entire cohort, in 17 of 24 (71%) pathologies, an anomaly colocalizing with the actual lesion was observed on ULF MRI. For 11 of 24 (46%) pathologies, the full diagnosis could be made based on ULF MRI. Tumors and posttraumatic lesions could be diagnosed best on ULF MRI, whereas cortical dysplasia and other focal pathologies were the least well diagnosed.This single-center series of individuals with epilepsy demonstrates the feasibility and utility of ULF MRI for the field of epileptology. Its integration into epilepsy care offers transformative potential, particularly in resource-limited settings. Further research is needed to position ULF MRI within imaging modalities in the diagnosis of epilepsy.
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 2
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Epilepsy
|2 Other
650 _ 7 |a Global Epileptology
|2 Other
650 _ 7 |a Neuroimaging
|2 Other
650 _ 7 |a Sustainability
|2 Other
650 _ 7 |a limited ressources
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging: methods
|2 MeSH
650 _ 2 |a Epilepsy: diagnostic imaging
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Adolescent
|2 MeSH
650 _ 2 |a Proof of Concept Study
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
700 1 _ |a Olbrich, Simon
|b 1
700 1 _ |a Groteklaes, Anne
|b 2
700 1 _ |a Lehnen, Nils Christian
|b 3
700 1 _ |a Zidan, Mousa
|b 4
700 1 _ |a Lange, Annalena
|b 5
700 1 _ |a Bisten, Justus
|b 6
700 1 _ |a Walger, Lennart
|0 0000-0002-3300-6877
|b 7
700 1 _ |a Faber, Jennifer
|0 P:(DE-2719)2811327
|b 8
|u dzne
700 1 _ |a Bruchhausen, Walter
|b 9
700 1 _ |a Vollmuth, Philipp
|b 10
700 1 _ |a Herrlinger, Ulrich
|b 11
700 1 _ |a Radbruch, Alexander
|0 P:(DE-2719)9001861
|b 12
|u dzne
700 1 _ |a Surges, Rainer
|b 13
700 1 _ |a Sabir, Hemmen
|0 P:(DE-2719)9000732
|b 14
|u dzne
700 1 _ |a Rüber, Theodor
|0 0000-0002-6180-7671
|b 15
|e Last author
773 _ _ |a 10.1111/epi.18171
|g Vol. 65, no. 12, p. 3607 - 3618
|0 PERI:(DE-600)2002194-X
|n 12
|p 3607 - 3618
|t Epilepsia
|v 65
|y 2024
|x 0013-9580
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/274005/files/DZNE-2024-01433.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/274005/files/DZNE-2024-01433.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:274005
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002598
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2811327
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)9001861
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)9000732
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 0000-0002-6180-7671
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 2
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-22
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EPILEPSIA : 2022
|d 2023-10-22
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2023-10-22
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-22
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-22
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EPILEPSIA : 2022
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-22
920 1 _ |0 I:(DE-2719)1013026
|k AG Stöcker
|l MR Physics
|x 0
920 1 _ |0 I:(DE-2719)1011001
|k Clinical Research (Bonn)
|l Clinical Research Coordination
|x 1
920 1 _ |0 I:(DE-2719)5000075
|k AG Radbruch
|l Clinical Neuroimaging
|x 2
920 1 _ |0 I:(DE-2719)5000032
|k AG Sabir
|l Neonatal Neuroscience
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1013026
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)5000075
980 _ _ |a I:(DE-2719)5000032
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21